Nitto-denko Corporation

Tolero Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

Jihua Liu

Wenbin Ying

Li Wang

Kenjirou Minomi

Bharat Majeti

Roger C Adami

Koc-Kan Ho

Yong Xu

Kenneth Mark Parnell

Xiaohui Liu

Michael David Saunders

Jason Marc Foulks

Kevin Bret Wright

Steven Brian Kanner

David Lee Vollmer

Scott Albert Pearce

Yoshiro Niitsu

Kwok Yin Tsang

Hao Bai

Haiqing Yin

Roger Adami

Akihiro Yoneda

Yasuaki Tamura

Micheal David Saunders

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-&#x3c0;.

Methods and compositions for treating malignant tumors associated with KRAS mutation

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor, which may be associated with KRAS mutation in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-&#x3c0;.

This invention provides compositions for use in distributing active agents for treating a malignant tumor in a subject. The compositions contain RNAi molecules targeted to a human GST-&#x3c0;, along with RNAi molecules targeted to a human p21, and a pharmaceutically acceptable carrier. The carrier can include nanoparticles composed of an ionizable lipid, a structural lipid, one or more stabilizer lipids, and a lipid for reducing immunogenicity of the nanoparticles. This invention further provides methods for preventing or treating a malignant tumor by administering a therapeutically effective amount of an RNAi composition.

RNA interference compositions and methods for malignant tumors

Methods and compositions for treating malignant tumors associated with kras mutation

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

PKM2 modulators and methods for their use

Polymer conjugates characterized in that the backbone of the polymer is an anionic polymer and hydrophobic moieties are covalently attached to the polymer backbone are useful for preparing drug encapsulated polymer hydrotropes and compositions. Such materials are useful in methods for delivering the drug into cells, and for the treatment and alleviation of diseases and disorders such as cancer.

Polymer-based hydrotropes for hydrophobic drug delivery

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Growing community of inventors

San Marcos, CA, United States of America

Jihua Liu